ER-Positive Metastatic Breast Cancer — A Roundtable Discussion on the Current and Future Role of Oral SERDs

<p class="MsoNormal">Featuring slide presentations and related discussion from Prof Francois-Clement Bidard, Dr Hope S Rugo, Dr Rebecca Shatsky and Dr Seth Wander, including the following topics:</p> <ul> <li>Optimal approach to biomarker testing for patients with ER-positive metastatic breast cancer (mBC) (0:00)</li> <li>Case: A woman in her early 70s with recurrent ER-positive, HER2-negative mBC receives elacestrant (15:15)</li> <li>Case: A woman in her early 60s with ER-positive, HER2-low, PIK3CA-mutated mBC receives inavolisib-based therapy and experiences no disease progression for 24 months (18:02)</li> <li>Role of oral selective estrogen receptor degrader (SERD) monotherapy in the treatment of progressive ER-positive, HER2-negative mBC (26:26)</li> <li>Case: A woman in her mid 60s with recurrent HR-positive, HER2-negative mBC receives elacestrant (44:12)</li> <li>Case: A woman in her early 50s with recurrent HR-positive, HER2-negative, PIK3CA-mutant mBC receives capivasertib and...